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We have retrospectively analysed the experience of a musculoskeletal oncological unit in the management of adult head and neck
soft tissue sarcomas from 1990 to 2005. Thirty-six patients were seen, of whom 24 were treated at this unit, the remainder only
receiving advice. The median age of the patients was 46 years. Most of the sarcomas were deep and of high or intermediate grade
with a median size of 5.5cm. Eleven diﬀerent histological subtypes were identiﬁed. Wide excision was possible only in 21% of the
cases. 42% of the patients developed local recurrence and 42% developed metastatic disease usually in the lungs. Overall survival
was 49% at 5 years. Tumour size was the most important prognostic factor. Adult head and neck soft tissue sarcomas have a high
mortality rate with a high risk of local recurrence and metastatic disease. The rarity of the disease would suggest that centralisation
of care could lead to increased expertise and better outcomes.
Copyright © 2008 Rabindra P. Singh et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Soft tissue sarcomas of the head and neck are rare mesenchy-
mal malignant neoplasms accounting for less than 10% of all
soft tissue sarcomas and approximately 1% of all head and
neck neoplasms [1–5]. Nevertheless, they represent an im-
portant group of tumours and are associated with signiﬁcant
morbidity and mortality.
Thereareseveralhistologicalsubtypesofsarcomaswhich
present with a variety of clinical characteristics and many
often require treatment with combination of surgery, radio-
therapy, and chemotherapy. They are best treated in special-
ist sarcoma units where expert multidisciplinary approach to
management is possible. In the UK, surgical management of
soft tissue sarcomas in the head and neck region is under-
taken by otolaryngologists, maxillofacial surgeons, as well as
by musculoskeletal sarcoma surgeons, depending on the lo-
cation of the lesion.
Reﬂecting the rarity of the disease, there is currently a
scarcity of studies in the literature and, to our knowledge,
there is only one published study that is based in a UK hos-
pital in the last 15 years [4]. Most of the series which are
p u b l i s h e dh a v er e p o r t e do u t c o m eo v e ran u m b e ro fd e c a d e s
possibly to compensate for the rarity of the disease and to in-
crease the size of the study sample for meaningful statistical
analysis [6]. However, the spanning of studies over several
decades has an important drawback in that changes in the
management of sarcomas and their outcome are not always
accurately reﬂected.
We report on our experience of the management of adult
head and neck soft tissue sarcomas presenting to a regional
sarcomacentrebasedatanorthopaedichospitaloverthepast
20 years.
2. METHODS
We have prospectively collected patient, tumour, treatment,
and outcome data on all patients with bone and soft tissue
sarcomas for over 20 years at the Royal Orthopaedic Hospital
(Birmingham, UK). We have identiﬁed all patients with soft2 Sarcoma
tissue sarcomas in the head and neck, deﬁned as sites above
the level of the clavicle. We have included all patients seen at
the unit between 1990 and 2005.
We have made a number of observations related to pa-
tient demographics, tumour variables, treatment modalities,
outcome, and follow up for patients with head and neck soft
tissue sarcomas. Tumours were classiﬁed as deep if they were
deep to the investing fascia whilst they were superﬁcial if
they lay purely in the subcutaneous tissues. The margins of
excision were classiﬁed according the method of Enneking
[7] with a wide margin being one in which a clear layer of
normal tissue lay between the tumour and the excision mar-
gin. A marginal excision was when the excision plane passed
throughthereactivezonearoundthetumour(clearbutclose)
and an intralesional excision was when tumour was incised
at any part of the operation, even if a subsequent wide ex-
cision was achieved. Survival was estimated using Kaplan
M e i e rs u r v i v a lc u r v e sa n dw a sd e t e r m i n e df o ro v e r a l l5 - y e a r
survival, and the log rank method was used to analyse the
inﬂuence of various prognostic factors on survival of the pa-
tients. For situations where no events had arisen in one sub-
group, chi-square testing was used to assess possible signiﬁ-
cance. Institutional approval for this study was obtained.
3. RESULTS
3.1. Patients
A total of 36 patients with head and neck softtissue sarcomas
were seen during the study period, 24 of whom were treated
at this unit. This is approximately 2% of the total 1912 cases
of all soft tissue sarcomas seen at this unit during the same
period. The median age of the patients was 46 years with a
range from 16 to 83 years. There were 24 male and 12 female
patients (M : F = 2:1 ) .
Thirty-ﬁve of the sarcomas were located in the neck
and one was located in the scalp. The average duration of
symptoms experienced by patients prior to diagnosis was 54
weeks(range1–416weeks)andthemostcommonlyreported
symptom was the presence of a painless lump.
The rest of the observations and analysis are based on the
24 patients who received treatment at this unit. We have ex-
cluded 12 patients who were either referred for advice only
(9 patients) and received deﬁnitive treatment elsewhere or
who presented with local recurrence and/or metastases after
previous failed treatment (3 patients). Various observations
on tumours, treatment, local control, and outcome are sum-
marised in Table 1.
3.2. Tumours
The median tumour size was 5.5cm (range 0.6–13cm) at di-
agnosis. 18 of the sarcomas (75%) were deep to the investing
fascia, the rest superﬁcial to the fascia. Two of the sarcomas
werelowgrade(18%),therestintermediate(42%,n = 10)or
high grades (50%, n = 12). All tumours which were located
deep to the fascia were of high or intermediate grade. Only
one patient (with a Ewing’s sarcoma) had lung metastases at
the time of presentation.
Eleven diﬀerent histological subtypes were identiﬁed, of
which malignant peripheral nerve sheath tumour (MPNST)
was the commonest subtype (25%, n = 6). The histological
subtypes are listed in Table 2.
3.3. Treatment
The principles of treatment used at the Unit during this time
consisted of planned wide local excision followed by radio-
therapy for all high-grade tumours >5cm or where there
were close margins of excision.
Eight patients were treated with surgery alone as initial
treatment for their sarcomas. 13 patients had surgery and
postoperative radiotherapy. Two of the three patients who
had Ewing’s sarcoma received neoadjuvant chemotherapy,
surgery, and postoperative radiotherapy; and one received
chemotherapy and surgery. The documented margins of ex-
cision were intralesional in 10 (42%), marginal in 9 (37%),
and wide in 5 (21%).
3.4. Localcontrol
The patients were followed up for an average period of 50
months. Local recurrence arose in 10 patients (42%) at a me-
dian time of 14 months (range 5–96 months) following ini-
tial treatment. One of the two patients with a low-grade su-
perﬁcial sarcoma developed local recurrence and 9 of the 22
with high- or intermediate-grade sarcomas developed local
recurrence. Local recurrence was strongly related to margins
achieved, arising in six of the ten with an intralesional mar-
gin (60%), three of the nine with a marginal margin (33%),
and one of the ﬁve with a wide margin (20%).
Of the ten patients who developed local recurrence, four
were either known to have systemic metastases already or
were found to have synchronous metastases at the time of
restaging. All four received palliative treatment and all died
at a median of 9 months from diagnosis of the local recur-
rence. Six patients with local recurrence had no evidence
of metastases when they developed the local recurrence and
were treated aggressively with further surgical excision and
radiotherapy when possible, often requiring extensive surgi-
cal reconstructions in order to obtain wide margins of exci-
sion. Two of these patients subsequently developed metas-
tases 6 and 12 months later, respectively, and both subse-
quently died. The other four patients remained disease-free
at a mean of 52 months following their local recurrence.
3.5. Metastases
Ten patients (42%) developed metastatic disease at a median
time of 17 months (range 0–139 months). Eight patients de-
veloped lung metastases and two lymph node metastases. All
ofthepatientswithconcomitantorpreviouslocalrecurrence
subsequently died as did two of the others without local re-
currence. Two patients underwent surgical resection of lung
metastases and remained alive and disease-free at a median
of 17 months.Rabindra P. Singh et al. 3
Table 1: Patient age, tumour factors, treatment, local recurrence, and outcome. MPNST: malignant peripheral nerve sheath tumour, DFSP:
dermatoﬁbrosarcoma protuberans, MFH: malignant ﬁbrous histiocytoma, SEF: sclerosing epithelioid ﬁbrosarcoma, CT: chemotherapy, RT:
radiotherapy.
Case
no.
Age
(yrs)
Diagnosis Size
(cm)
Depth Trojani grade Deﬁnitive treatment Surgical
margin
Local
recurrence
(months)
Outcome
(months)
13 8Leiomyosarcoma 0.6 Subcutaneous High Excision Wide Alive, 45
22 2Ewing’s sarcoma 1.5 Deep High CT + excision Wide Alive, 208
34 1DFSP 1.7 Subcutaneous Intermediate Excision Marginal Alive, 20
42 4DFSP 2 Subcutaneous Low Excision Wide Alive, 37
51 9MPNST 3 Subcutaneous Intermediate Excision Wide Alive, 36
62 0Ewing’s sarcoma 4 Deep High CT + excision + RT Intralesional Alive, 74
74 1Spindle cell sarcoma 4 Deep Intermediate Excision Intralesional 8 Alive, 21
86 4Spindle cell sarcoma 4 Deep Intermediate Excision + RT Marginal 16 Died, 33
93 9MPNST 5 Deep High Excision + RT Intralesional 26 Died, 52
10 53 SEF 5 Deep Intermediate Excision Wide 49 Alive, 139
11 62 Myxoid chondrosarcoma 5 Deep Intermediate Excision Marginal 96 Alive, 157
12 77 MFH 6 Deep High Excision + RT Intralesional 5 Died, 22
13 54 Myxoﬁibrosarcoma 6.5 Deep High Excision + RT Marginal Alive, 14
14 22 Synovial sarcoma 7 Deep High Excision + RT Intralesional Alive, 35
15 38 MPNST 7 Deep High Excision + RT Intralesional Died, 14
16 50 MPNST 7 Deep Intermediate Excision + RT Marginal Alive, 191
17 65 Liposarcoma 7 Deep High Excision + RT Intralesional 12 Died, 16
18 32 MPNST 8 Deep Intermediate Excision + RT Marginal Alive, 13
19 68 Spindle cell sarcoma 9 Subcutaneous High Excision + RT Wide Alive, 12
20 73 Liposarcoma 9 Deep High Excision + RT Intralesional 41 Died, 51
21 30 Ewing’s sarcoma 10 Deep High CT + excision + RT Intralesional 12 Died, 14
22 48 Synovial sarcoma 10 Deep Intermediate Excision + RT Marginal Alive, 11
23 65 MPNST 10 Deep Intermediate Excision + RT Marginal Died, 45
24 33 Liposarcoma 13 Subcutaneous Low Excision Marginal 8 Alive, 51
Table 2: Histological subtypes. MPNST: malignant peripheral
nerve sheath tumour, DFSP: dermatoﬁbrosarcoma protuberans,
MFH: malignant ﬁbrous histiocytoma, SEF: sclerosing epithelioid
ﬁbrosarcoma.
Subtypes No. of patients (%)
MPNST 6 (25%)
Ewing’s sarcoma 3 (13%)
Liposarcoma 3 (13%)
Spindle cell sarcoma 3 (13%)
Synovial sarcoma 2 (8%)
DFSP 2 (8%)
Myxoﬁbrosarcoma 1 (4%)
Leiomyosarcoma 1 (4%)
MFH 1 (4%)
Myxoid Chondrosarcoma 1 (4%)
SEF 1 (4%)
3.6. Survival
Eight patients died at a median time of 2.3 years from diag-
nosis. Overall survival was 48.6% at ﬁve years but with wide
conﬁdence limits (plus or minus 13%) (Figure 1). We inves-
tigated the following factors for possible signiﬁcance on sur-
vival.
(i) Size. Only 1 patient with a primary sarcoma >5cmhas
yet survived more than 5 years whilst the survival for
patients with tumours ≤5cm was 71% at 5 years (p =
0.02) (Figure 2).
(ii) Grade. Neither of the two patients with low-grade tu-
mours died but 8 of the 22 with high- or intermediate-
grade tumours died (P = .29) (chi-square).
(iii) Depth. None of the 6 patients with subcutaneous sar-
comas died but 8 of the 18 with deep tumours died
(P = .0455) (chi-square).
(iv) Margin. Six of the 10 patients with intralesional and
two of the 9 patients with a marginal surgical margin
died, however none of the 5 patients with a wide sur-
gical margin died (P = .04).
(v) Age. We could ﬁnd no eﬀect of age on survival.
Combining these factors revealed that all deaths arose in
the patients with high- or intermediate-grade deep tumours.
When further stratiﬁed by size, this showed that two of the
seven patients with high-grade deep tumours ≤5cm died4 Sarcoma
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Figure 1: Overall 5-year survival.
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Figure 2: Overall survival by size of sarcoma.
compared with 6 of the 11 with high-grade deep tumours
>5cm(P = .04).
4. DISCUSSION
Head and neck sarcomas are rare and the paucity of stud-
ies about their management and outcome testiﬁes to this.
Head and neck lumps are common and have a variety of
diagnoses [2, 3]. Early detection and diagnosis is clearly es-
sential. The National Institute for Health and Clinical Excel-
lence (NICE) guidance 2005 to all UK general practitioners
emphasises that “In patients with an unexplained lump in the
neck which has recently appeared or a lump which has not been
diagnosed before that has changed over a period of 3 to 6 weeks,
an urgent referral should be made” [8]. Whilst more general
advice is also given about lumps elsewhere in the body: “In
patients presenting with a palpable lump, an urgent referral for
suspicion of soft tissue sarcoma should be made if the lump is
(i) greater than about 5cm in diameter,
(ii) deep to fascia, ﬁxed, or immobile,
(iii) painful,
(iv) increasing in size,
(v) a recurrence after previous excision.”
Our unit is a musculoskeletal unit that takes referrals of pa-
tients with both proven or suspected sarcomas. In the case of
the headand neck tumours, some were referreddirectly tous
forinvestigationanddiagnosiswhilstotherswerereferredaf-
ter a biopsy or imaging had conﬁrmed the diagnosis of a sar-
coma. We treated patients with sarcomas that were conﬁned
tothesuperﬁcialtissuesordeepmusclesoftheheadandneck
and we have not included patients with soft tissue sarcomas
involving the facial skeleton or the oropharynx which pose
even greater challenges in treatment [6].
Our management policy was based on principles used in
treatingsofttissuesarcomasatothersites.Theheadandneck
poses particular problems however because of the proxim-
ity of so many important structures and the near impossibil-
ity of obtaining wide surgical margins in many cases. Unlike
limb soft tissue sarcomas,there is nofallbackoption of doing
an amputation if local recurrence arises.
The local recurrence rates for high-grade soft tissue sar-
comasaftersurgicalexcisionhavebeenreportedtobeashigh
as 50% in the literature [3, 9, 10]. 42% of patients developed
local recurrence in our study, most arising within 2 years of
treatment. Barker et al. in their study reported the median
time to local recurrence after treatment with surgery and/or
radiotherapy to be 4 months, and Kraus et al. reported that
patientswhodevelopedlocalrecurrencedidsowithin3years
[11, 12].
The risk of local recurrence was higher with intralesional
or marginal surgical margins as has been shown by other au-
thors [2, 12]. In view of this, every eﬀort should be made to
maximise the margins that can be achieved at the time of the
ﬁrst surgical procedure, if necessary by going back and doing
a further wide excision if the initial margins prove positive.
All patients should have their case discussed at a multidisci-
plinary teammeeting and the option of radiotherapy consid-
ered to try and decrease the risk of local recurrence. Even if
patients do develop local recurrence, their case is not hope-
less and further excision should be considered. Clearly, how-
ever,initialwidesurgicalmarginsshouldalwaysbeaimedfor.
The commonest site for metastases was the lungs which
was also the commonest cause of death. Mendenhall et al.
[3] suggested that patients should undergo a chest CT be-
fore treatment and also suggested that in the absence of pul-
monary metastases, other distant metastases are highly un-
likely. We concur with this.
T h e5 - y e a rs u r v i v a lr a t eo f4 9 %i no u rs t u d y( Figure 1)i s
comparable to a previous UK study by Eeles et al. [4]b a s e d
at the Royal Marsden Hospital of London. They analysed 103
cases seen over 44 years between 1944 and 1988 and reported
50% overall 5-year survival rate. This is similar to the results
reported by Bentz et al. [6] from Memorial Sloan Kettering
Cancer Centre. Most authors agree that the same prognostic
factorsapplytosarcomasnomatterwheretheyarise—grade,
size, and depth. In the head and neck, however, local recur-
rence has more sinister portents because of the diﬃculty of
subsequent management [5, 13–18].
Obtaining local control is paramount in managing these
head and neck sarcomas. Obtaining wide margins may of-
ten require a multidisciplinary team consisting of a sar-
coma surgeon, a head and neck surgeon and a reconstructiveRabindra P. Singh et al. 5
surgeon. A clinical oncologist is an essential part of the team
to advise about radiotherapy usage. A metaanalysis pub-
lished in Lancet revealed that chemotherapy did not pro-
duce a survival beneﬁt in the treatment of soft tissue sarco-
mas [19]. The same analysis did, however, show a 10% ben-
eﬁt of chemotherapy on recurrence-free survival. Adjuvant
chemotherapy is not usually advocated for localised soft tis-
sue sarcomas but can be considered for metastatic disease as
a palliative treatment.
Recent guidance from NICE, UK [20] in the manage-
ment of patients with sarcomas has highlighted the impor-
tance of referring all patients with soft tissue sarcomas to a
sarcoma centre where they can be managed by a multidis-
ciplinary team (MDT). The guidance has also emphasised
the importance of close collaboration between these sarcoma
MDTs and site-speciﬁc head and neck surgeons and oncolo-
gists. This has been emphasised by the recent paper of Harb
et al. [21]. We recommend that all surgeons who identify a
suspected or proven soft tissue sarcoma of the head and neck
should refer that patient to a sarcoma MDT and that all head
and neck cancer MDTs should have close links with the local
sarcoma MDT for management of these cases.
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